Search judgments by proposition, citation, court, judge or legal topic, then move directly into the source-grounded case analysis.
Results update automatically as you type.
Canada decisions
Decisions matching the current search
The Federal Court dismissed AbbVieâs judicial review. It held the Minister reasonably treated âanother drugâ under the PM(NOC) Regulations as DIN-specific and marketed in Canada.
The Court of Appeal dismissed an appeal in a product liability action over the EVRA patch, upholding refusal to strike the pleadings and summary dismiss the claim.
The Federal Court ordered common invalidity issues in two Patented Medicine (Notice of Compliance) actions to be tried concurrently to save time and resources.
The Federal Court allowed Dr. Doshiâs judicial review, finding Health Canada unreasonably imposed a confidentiality requirement for clinical trial data under Vanessaâs Law.
La Cour fĂ©dĂ©rale a fixĂ© les paramĂštres du calcul des dommages de Teva au titre de lâart. 8, en retenant le 26 aoĂ»t 2010 comme dĂ©but de la pĂ©riode de responsabilitĂ©.
La Cour fĂ©dĂ©rale a rejetĂ© la demande de contrĂŽle judiciaire dâApotex, concluant que lâexigence de renseignements supplĂ©mentaires sur lâintĂ©gritĂ© des donnĂ©es Ă©tait ni entachĂ©e par lâimport ban ni dĂ©raisonnable.
Federal Court upheld Pharmascienceâs non-infringement and overbreadth challenges to claim 1 of the '988 Patent, but rejected anticipation, obviousness, and utility attacks.
The Federal Court ordered a partial consolidation of related PM(NOC) proceedings, allowing the prohibition application and impeachment action to be heard together on one viva voce record.
Motion to bifurcate granted in a section 8 PM(NOC) action. The Court ordered hypothetical infringement and validity of the â287 and â172 patents tried first.
The Supreme Court of Canada dismissed an appeal in a PM(NOC) Regulations damages case, upholding findings on the 24-month liability period, generic entry timing, market share, and lost sales.
Explore more
